Investor Presentaiton
Formulations : Sustaining growth momentum.
Key Updates
EUROPE-
Return to growth with launch of new Phyto range. Structural adjustments to improve margins
Manufacturing in Germany discontinued and operations to shift to alternative low cost locations.
Margin accretive from Q3 FY 24
EMERGING MARKETS -
Nourrie integration completed in Brazil. New platform created for companion animals. Turkey
business impacted by inflationary pressures and the recent earthquake.
INDIA-
Cattle business continues to grow by ~10% despite challenges in rural markets. Expansion of team
for accelerated growth in FY 24
1,878
6,789
2,451
Revenues
14%
9,686
8,824
2,494
J Sequent
Proven Ability In Life Sciences
ALIVIRA
FDFs
1000+
Manufacturing
facilities
6
All values in * Mn
R&D Centres
4
2,559
10,009
Q4 FY20 FY20
Q4 FY21 FY21
Q4 FY22 FY22
Q4 FY23 FY23
cc- Constant Currency
Countries with
marketing
80+
presence
6View entire presentation